Related Experiment Videos
Antileukotrienes in chronic urticaria
The Journal of Allergy and Clinical Immunology
|May 9, 1998
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
The Submental Nasal Appearance Scale for the Assessment of Repaired Unilateral Complete Cleft Lip: A Validation Study.
The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association·2020
Driven dynamics and rotary echo of a qubit tunably coupled to a harmonic oscillator.
Physical review letters·2012
Arginine deprivation as a targeted therapy for cancer.
Current pharmaceutical design·2008
Illumination for coherent soft X-ray applications: the new X1A beamline at the NSLS.
Journal of synchrotron radiation·2006
Omalizumab: efficacy in allergic disease.
Panminerva medica·2004
TNF-alpha is a master regulator of drug-specific T-cell activation.
The Journal of allergy and clinical immunology·2026
Decoding the epithelial-stromal interactome in allergic rhinitis through single-cell multi-omics integration.
The Journal of allergy and clinical immunology·2026
IgE-Sensitized Mast Cells Release Extracellular Vesicles that Transfer IgE and Spread Allergic Sensitization.
The Journal of allergy and clinical immunology·2026
Post-GWAS Variant-to-Function Challenges in Asthma Research.
The Journal of allergy and clinical immunology·2026
AMPK-driven immunometabolic reprogramming enhances CD19<sup>+</sup>CD21<sup>hi</sup>CD24<sup>hi</sup> regulatory B cell-mediated suppression of atopic dermatitis.
The Journal of allergy and clinical immunology·2026
Comparative Efficacy of Biologic Agents for Severe Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Network Meta-analysis.
The Journal of allergy and clinical immunology·2026
Upadacitinib for refractory generalized lichen sclerosus: a case report and brief literature review.
Frontiers in immunology·2026
Case Report: A case report of bullous pemphigoid triggered by sintilimab (PD-1 inhibitor).
Frontiers in immunology·2026